Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD decreased its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 24.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 41,286 shares of the company’s stock after selling 13,616 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Ventyx Biosciences were worth $91,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in VTYX. American Century Companies Inc. lifted its holdings in Ventyx Biosciences by 12.4% in the 4th quarter. American Century Companies Inc. now owns 67,329 shares of the company’s stock valued at $147,000 after purchasing an additional 7,414 shares in the last quarter. Wells Fargo & Company MN increased its stake in Ventyx Biosciences by 23.3% during the fourth quarter. Wells Fargo & Company MN now owns 41,170 shares of the company’s stock worth $90,000 after purchasing an additional 7,768 shares during the period. Barclays PLC grew its position in shares of Ventyx Biosciences by 14.2% during the fourth quarter. Barclays PLC now owns 91,669 shares of the company’s stock worth $200,000 after buying an additional 11,374 shares in the last quarter. Catalina Capital Group LLC acquired a new position in shares of Ventyx Biosciences during the fourth quarter worth about $25,000. Finally, MetLife Investment Management LLC boosted its holdings in Ventyx Biosciences by 76.0% in the fourth quarter. MetLife Investment Management LLC now owns 26,731 shares of the company’s stock valued at $59,000 after purchasing an additional 11,543 shares in the last quarter. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Trading Up 15.7%

VTYX stock opened at $1.40 on Monday. Ventyx Biosciences, Inc. has a twelve month low of $0.78 and a twelve month high of $5.66. The business has a 50 day simple moving average of $1.19 and a 200-day simple moving average of $1.76. The company has a market capitalization of $99.63 million, a P/E ratio of -0.59 and a beta of 0.73.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.09. Research analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.